To include your compound in the COVID-19 Resource Center, submit it here.

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 3/13 cls
Genmab (CSE:GEN) UBS Guillaume van Renterghem Upgrade Buy (from neutral) 0% DKK221.25
van Renterghem upgraded in anticipation of FDA acceptance and potential Priority Review of a BLA for Arzerra ofatumumab to treat chronic lymphocytic leukemia (CLL). He expects acceptance in the coming weeks and approval of the mAb against

Read the full 765 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE